MARKET

ALRN

ALRN

Aileron Therapeutics Inc
NASDAQ
4.005
+0.005
+0.13%
Opening 09:34 11/05 EST
OPEN
3.990
PREV CLOSE
4.000
HIGH
4.075
LOW
3.940
VOLUME
5.45K
TURNOVER
--
52 WEEK HIGH
7.42
52 WEEK LOW
1.190
MARKET CAP
86.77M
P/E (TTM)
-1.2337
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALRN last week (1028-1101)?
Weekly Report · 1d ago
Aileron Therapeutics’ ALRN-6924 to be acquired by Advancium Health Network
TipRanks · 5d ago
*Advancium Paid Aileron Non-Refundable Fee for Exclusive Option to Acquire ALRN-6924 and Related Assets >ALRN
Dow Jones · 5d ago
Aileron Therapeutics And Advancium Health Network Announced An Exclusive Option Agreement For The Acquisition Of ALRN-6924, Developed By Aileron Prior To Its 2023 Merger With Lung Therapeutics
Benzinga · 5d ago
*Advancium Will Evaluate ALRN-6924 as a Potential Therapy for Retinoblastoma
Dow Jones · 5d ago
*Aileron Therapeutics: Agreement Marks First of Its Kind for Advancium, a Public Charity Launched by Deerfield
Dow Jones · 5d ago
AILERON THERAPEUTICS AND ADVANCIUM HEALTH NETWORK ANNOUNCE AN EXCLUSIVE OPTION AGREEMENT FOR THE ACQUISITION OF ALRN-6924 FOR RETINOBLASTOMA
Reuters · 5d ago
Press Release: Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Dow Jones · 5d ago
More
About ALRN
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Webull offers Aileron Therapeutics Inc stock information, including NASDAQ: ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALRN stock methods without spending real money on the virtual paper trading platform.